APP and Alzheimer disease: 44. Composite Therapeutic Strategy for Symptomatic AD: The Dual Duty of the Neuronal ISR Inhibitors Administered Concurrently with the Activators of BACE Enzymes—(1) Enabling the Continuous Production of BACE1 and BACE2 and (2) Ceasing the Influx of iAβ Produced in the AβPP-Independent Pathway